Patents by Inventor Thomas ALANINE

Thomas ALANINE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11724988
    Abstract: The present invention relates to processes of preparing N-((1,2,3,4,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-iso-propyl-1H-pyrazole-3-sulfonamide and salts thereof. The present invention further relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: August 15, 2023
    Assignee: INFLAZOME LIMITED
    Inventors: Daniel Schwizer, Sascha Breeger, Stephen Thom, Thomas Alanine
  • Publication number: 20230121952
    Abstract: The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl triazoles. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: February 16, 2021
    Publication date: April 20, 2023
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Stephen THOM, Jonathan SHANNON, Celia Amparo INCERTI-PRADILLOS, Thomas ALANINE, Shawn JOHNSTONE, Juliette SABBATANI
  • Patent number: 11613542
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with a nitrogen-containing group R1? wherein R1 contains from 1 to 7 atoms other than hydrogen or halogen. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: March 28, 2023
    Assignee: Inflazome Limited
    Inventors: Matthew Cooper, David Miller, Angus Macleod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon, Thomas Alanine, Stuart Onions, Ian Strutt, Jokin Carrillo Arregui
  • Patent number: 11542255
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, wherein at least one of the di-substituents contains a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: January 3, 2023
    Assignee: INFLAZOME LIMITED
    Inventors: Matthew Cooper, David Miller, Angus MacLeod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon, Thomas Alanine, Stuart Onions, Ian Strutt
  • Publication number: 20220289766
    Abstract: The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl ureas. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 15, 2022
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Thomas ALANINE, Stephen THOM, Jonathan SHANNON, Jokin CARRILLO ARREGUI, Stephen ST-GALLAY
  • Publication number: 20220106288
    Abstract: The present invention relates to compounds of formula (I): wherein A, B, X, Y, R1, R4 and R7 are as defined in the specification. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Application
    Filed: August 12, 2019
    Publication date: April 7, 2022
    Inventors: Angus MACLEOD, Jonathan SHANNON, Stephen THOM, Jokin CARRILLO ARREGUI, Thomas ALANINE
  • Publication number: 20220064125
    Abstract: The present invention relates to processes of preparing N-((1,2,3,4,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-iso-propyl-1H-pyrazole-3-sulfonamide and salts thereof. The present invention further relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: October 18, 2019
    Publication date: March 3, 2022
    Inventors: Daniel SCHWIZER, Sascha BREEGER, Stephen THOM, Thomas ALANINE
  • Publication number: 20210261512
    Abstract: The present invention relates to substituted 5-membered nitrogen containing heteroaryl compounds, such as sulfonyl triazoles, where the heteroaryl ring is further substituted, optionally via a linking group such as —NH—, with a cyclic group which in turn is substituted at the ?-position. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 26, 2021
    Applicant: INFLAZOME LIMITED
    Inventors: David MILLER, Angus MACLEOD, Stephen THOM, Christopher G. MCPHERSON, Thomas ALANINE, Jokin CARRILLO ARREGUI, Claire-Lise CIANA, Jonathan SHANNON, Jimmy VAN WILTENBURG, Jacobus Antonius Joseph DEN HARTOG
  • Publication number: 20210163412
    Abstract: The present invention relates to compounds of formula (I): wherein A, B, L, X, Y, R1, R2 and R4 are as defined in the specification. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Application
    Filed: August 12, 2019
    Publication date: June 3, 2021
    Inventors: Jonathan SHANNON, Stephen THOM, Jokin CARRILLO ARREGUI, Thomas ALANINE
  • Publication number: 20210130329
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is di-substituted at the 3- and 4-positions relative to the point of attachment of the sulfonyl group, wherein at least one of the di-substituents contains a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Application
    Filed: August 15, 2018
    Publication date: May 6, 2021
    Applicant: Inflazome Limited
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON, Thomas ALANINE, Stuart ONIONS, Ian STRUTT
  • Publication number: 20210130359
    Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with a nitrogen-containing group R1? wherein R1 contains from 1 to 7 atoms other than hydrogen or halogen. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Application
    Filed: August 15, 2018
    Publication date: May 6, 2021
    Applicant: Inflazome Limited
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON, Thomas ALANINE, Stuart ONIONS, Ian STRUTT, Jokin CARRILLO ARREGUI
  • Publication number: 20200361895
    Abstract: The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; and R2 is a cyclic group substituted at the ?-position with a monovalent heterocyclic group or a monovalent aromatic group, wherein a ring atom of the heterocyclic or aromatic group is directly attached to the ? ring atom of the cyclic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the cyclic group may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
    Type: Application
    Filed: August 15, 2018
    Publication date: November 19, 2020
    Applicant: Inflazome Limited
    Inventors: Matthew COOPER, David MILLER, Angus MACLEOD, Jimmy VAN WILTENBURG, Stephen THOM, Stephen ST-GALLAY, Jonathan SHANNON, Thomas ALANINE, Stuart ONIONS, Ian STRUTT